Vimta Labs Limited

Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051, India

T: +91 40 2726 4141 F: +91 40 2726 3657



VLL\10\S-004\2019\ Date: 06.02.2019

Listing Centre
B S E Limited
P J Towers, Dalal Street
Mumbai: 400001

Attn: Listing Centre

Scrip Code No.524394.

Asst Vice President
National Stock Exchange of India Limited
"Exchange Plaza", Bandra
Kurla Complex, Bandra (E)
Mumbai – 400 0051

Kind Attn: Mr. K Hari.

Trading Symbol: VIMTA LABS

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing obligations and disclosure requirements) 2015, please find enclosed herewith unaudited Financial Results for the 3rd Quarter ended December 31, 2018 along with Limited Review Report.

Copy of the Unaudited Financial results are also posted on the company's website i.e. http://www.vimta.com/financials.

Abridged financial are being published in the newspapers (copy enclosed)

This is for your information and records.

Thanking you,

Yours faithfully,

for VIMTA LABS LIMITED

SUJANI VASIREDDI Company Secretary

Encl: as above.

CIN: L24110TG1990PLC011977

Vimta Labs Limited

Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051, India

T: +91 40 2726 4141 F: +91 40 2726 3657



Statement of Unaudited Financial Results for the Quarter and Nine Months ended 31 December 2018 (Amount in INR millions, except Earnings Per Share)

S. No.	Particulars		Quarter ended		Nine Months ended		Year ended	
		31 Dec 18	30 Sep 18	31 Dec 17	31 Dec 18	31 Dec 17	31 Mar 18	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Income							
	(a) Revenue from operations	506.86	538.26	464.47	1,590.58	1,275.05	1,834.5	
	(b) Other Income	0.20	9.99	3.67	17.49	11.59	11.97	
	Total Income	507.06	548.25	468.14	1,608.07	1,286.64	1,846.48	
2	Expenses							
_	(a) Cost of materials consumed and testing	141.43	136.37	125.03	423.39	366.45	502.64	
	expenditure	141.43	130.37	123.03	423.39	300.43	302.04	
	(b) Purchase of stock-in-trade	-	-	-	-		-	
	(c) Changes in inventories of work-in-progress	(11.66)	1.23	(10.15)	(5.31)	(16.50)	23.5	
	(d) Employee benefits expense	149.13	149.18	128.75	444.45	376.88	536.4	
	(e) Finance Costs	3.24	20.29	14.05	41.81	40.70	52.00	
	(f) Deprecation and amortisation expense	49.24	48.25	43.25	144.80	110.46	157.00	
	(g) Other expenses	92.34	92.45	82.87	291.48	231.84	319.2	
	Total Expenses	423.72	447.77	383.80	1,340.62	1,109.83	1,590.84	
3	Profit/(Loss) before exceptional items and tax	83.34	100.48	84.34	267.45	176.81	255.64	
	[1-2]							
4	Exceptional items	-	-	-	-	-	2	
5	Profit/(Loss) before tax [3-4]	83.34	100.48	84.34	267.45	176.81	255.64	
6	Tax expense							
	(a) Current tax	27.92	33.27	19.00	95.52	50.90	76.9	
	(b) Taxes of earlier periods	7.81	(2.32)	-	5.49	2.40	2.40	
	(c) Deferred tax (benefit)/expense	(3.56)	(0.14)	5.62	(18.99)	9.85	12.00	
	Total Tax Expense	32.17	30.81	24.62	82.02	63.15	91.31	
7	Profit/(Loss) for the period (5-6)	51.17	69.67	59.72	185.43	113.66	164.33	
8	Other Comprehensive Income/(expense), net							
	of tax expenses							
	Items that will not be reclassified							
	subsequently to profit or loss :							
	(a) Re-measurements of net defined benefit liability	(1.45)	(4.72)	(2.07)	(6.56)	(6.21)	(8.08)	
- 1	(b) Income tax relating to the items	0.42	1.38	0.72	1.91	2.15	2.80	
	Total other comprehensive income, net of tax	(1.03)	(3.34)	(1.35)	(4.65)	(4.06)	(5.28	
	T-1-16	F0.4:			/	,		
	Total Comprehensive Income for the period (comprising Profit / (Loss) and other	50.14	66.33	58.37	180.78	109.60	159.05	
	Comprehensive income for the period [7+8]							
	Paid-up Equity Share Capital (face value of Rs.2/- each)	44.22	44.22	44.22	44.22	44.22	44.22	
11	Other Equity						1,476.31	
							,	
	Earnings per equity share (EPS) (Face value of							
	Rs.2 per share)							
	(a) Basic (INR)	2.32	3.15	2.70	8.39	5.14	7.43	
	(b) Diluted (INR)	2.32	3.15	2.70	8.39	5.14	7.43	
	(EPS for the quarter/nine months ended are							
	not annualised)					IARC		
- 1					MAR	100		

Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamirpet My erabat? 500 101, India

T: +91 40 6740 4040 E: mdoffice@vimta.com URL: www.vimta.com BASS

CIN: L24110TG1990PLC011977



Notes to the results:

- 1 The unaudited financial results for the quarter and nine months ended December 31, 2018 were reviewed by the Audit Committee and approved by the Board of Directors of the company at its meeting held on February 06, 2019. The Statutory Auditors of the company have carried out the limited review of the aforesaid results.
- 2 This statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These unaudited financials results of the Company were prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder (IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS-108, "Operating segment" and states that the Company has only one reportable segment namely "Contract Research and Testing Services".
- 4 Corresponding quarter/year figures have been re-grouped/re-classified wherever necessary to conform to the classification of the current period.

For and on behalf of the Board of Directors of

Vimta Labs Limited

Harita Vasireddi Managing Director

Place: Hyderabad, INDIA Date: February 06, 2019



GATTAMANENI & CO. CHARTERED ACCOUNTANTS

#10, Master Sai Apartments, Sangeet Nagar, Somajiguda, Hyderabad - 500 082.

Phone: 2339 6336 Mobile: 98497 68009

E-mail: gattamaneni_gs@yahoo.com

LIMITED REVIEW REPORT

Review Report to the Board of Directors of VIMTA LABS LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/s VIMTA LABS LIMITED, for the quarter ended 31-12-2018 and the year to date results for the period 1st April 2018 to 31st December 2018, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards specified under 133 of the Companies Act. 2013 read with SEBI Section CIR/CFD/CMD/15/2015 dated 30th November 2015 and CIR/CFD/FAC/62/2016 dated 5th July 2016, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad Date: 06-02-2019

G. SRINIVASARAO

for GATTAMANENI & CO. Chartered Accountants (Firm Regn.No.93Ø3S)

Partner ICAI Ms. No.210535

Vimta Labs Limited

Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051, India

T: +91 40 2726 4141 F: +91 40 2726 3657



Statement of Unaudited Financial Results for the Quarter and Nine Months ended 31 December 2018 (Amount in INR millions, except Earnings Per Share)

S. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31 Dec 18	30 Sep 18	31 Dec 17	31 Dec 18	31 Dec 17	31 Mar 18
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total Income from Operations	506.86	538.26	464.47	1,590.58	1,275.05	1,834.51
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	83.34	100.48	84.34	267.45	176.81	255.64
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	83.34	100.48	84.34	267.45	176.81	255.64
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	51.17	69.67	59.72	185.43	113.66	164.33
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	50.14	66.33	58.37	180.78	109.60	159.05
7	Equity Share Capital Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	44.22	44.22	44.22	44.22	44.22	44.22 1,476.31
10000	Earnings Per share (of Rs.2/- each) (for continuing and discontinued Operations)						
- 1	1. Basic (INR) 2. Diluted (INR)	2.32 2.32	3.15 3.15	2.70 2.70	8.39 8.39	5.14 5.14	7.43 7.43

Note:

- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's Website (www@vimta.com) and on the websites of BSE Limited (www.bseindia.com) and the National Stock Exchange of India Limited (www.nseindia.com).
- 2. The financial results of the company for the quarter and nine months ended December 31, 2018 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 06, 2019 and the Limited review of the same has been carried out by the Statutory Auditors.
- 3. Figures of the previous periods have been regrouped/recast/reclassified, wherever considered necessary.

For and on behalf of the Board of Directors of

Comme

Vimta Labs Limited

Harita Vasireddi Managing Director

Place: Hyderabad, INDIA Date: February 06, 2019



CIN: L24110TG1990PLC011977